Explainable Artificial Intelligence (xAI) for 5-HT

Verena Schöning, Katharina Elisabeth Grafinger, Daniel Pasin, Christophe P Stove, Wolfgang Weinmann, Felix Hammann

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Verena SchöningClinical Pharmacology & Toxicology, Department of Internal Medicine, University Hospital Bern, 3010 Bern, Switzerland.ORCID 0000-0003-2105-326X

Katharina Elisabeth GrafingerInstitute of Forensic Medicine Bern, Forensic Toxicology and Chemistry, University of Bern, 3008 Bern, Switzerland.ORCID 0000-0002-3647-7455

Daniel PasinHyperion Data, Griffith, NSW 2680, Australia.

Christophe P StoveLaboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0001-7126-348X

Wolfgang WeinmannInstitute of Forensic Medicine Bern, Forensic Toxicology and Chemistry, University of Bern, 3008 Bern, Switzerland.ORCID 0000-0001-8659-1304

Felix HammannClinical Pharmacology & Toxicology, Department of Internal Medicine, University Hospital Bern, 3010 Bern, Switzerland.ORCID 0000-0003-0658-9330

Funding

Swiss National Science Foundation SNF_10000358

6 · The paper itself

Abstract

New psychoactive substances (NPS) are a heterogeneous group of recreational drugs that mimic the actions and psychoactive effects of existing pharmaceutical products or recreational drugs. As NPS can be highly potent, even exceeding their template compound's potency, there are frequent reports of non-fatal and fatal intoxications. One principal target for hallucinogenic and psychedelic drugs, including NPS, is the 5-hydroxytryptamine receptor 2A (5-HT

Indexed as

Artificial IntelligencePsychotropic DrugsReceptor, Serotonin, 5-HT2AHumansLigandsMachine LearningProtein BindingLigandsPsychotropic DrugsReceptor, Serotonin, 5-HT2A5-HT2Abinding affinityclassification modelexplainable artificial intelligencemachine learningNPS

Identifiers

PMID42280191

DOI10.3390/molecules31111888

PMCPMC13257649

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.